Saltar al contenido
Merck

BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

IDrugs : the investigational drugs journal (2004-01-20)
R Todd Reilly
RESUMEN

BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Mesna impurity D, European Pharmacopoeia (EP) Reference Standard